Baxter's shares fall as 2026 profit guidance disappoints. Q4 EPS at 44 cents, sales reach $2.974 billion, up 8% yoy.

Baxter International Inc. (NYSE: BAX) is currently trading near the lower end of its 52-week range between $17.4 and $37.74, as per data from Benzinga Pro. In the fourth quarter, Baxter reported an adjusted EPS of 44 cents, falling short of both the management guidance range of 52-57 cents and the Wall Street estimate of 54 cents. This decrease was mainly attributed to an unfavorable product mix. The company achieved sales of $2.974 billion in the quarter, marking an 8% increase year over year on a reported basis and a 3% increase on an operational basis, surpassing the consensus of $2.824 billion. Management had initially anticipated a 2% growth in fourth-quarter sales on a reported basis and a 2% decline on an operational basis. Medical Products & Therapies segment sales accounted for around $1.39 billion, showing a 6% increase on a reported basis and a 4% increase on an operational basis.